# Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

> **NCT00377598** · PHASE2,PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 399 (actual)

## Conditions studied

- Neuralgia, Postherpetic

## Interventions

- **DRUG:** TAK-583
- **DRUG:** TAK-583
- **DRUG:** TAK-583
- **DRUG:** TAK-583
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00377598
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2012-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00377598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00377598, "Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00377598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*